Skip to content
中文产业新闻精选评分76Chinese source

天广实奥妥珠单抗β治疗NMOSD三期结果登《Nature Medicine》，复发风险降低97.9%

醴泽Portfolio | 「天广实」倍捷欣®治疗NMOSD降低97.9%复发风险，III期研究成果发表于《Nature Medicine》

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.